glp-1 obesity drugs news today New research is challenging long-held assumptions about in weight loss treatments. A different approach may be emerging. Click the link in bio to read the full story A new wave of weight-loss
Description
Learn about the Ozempic blindness lawsuit, including NAION and other vision problems, and read about the study linking semaglutide use to severe eye problems.
The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.
Learn about the Zepbound blindness lawsuit, including NAION and other eye side effects, and read about a study linking GLP-1 RAs to severe vision problems.
GLP-1s, produced in the gut, regulate blood sugar, appetite, and weight
Discover the benefits, mechanisms, and latest applications of GLP-1 receptor agonists in diabetes and obesity treatment.
